Urolastic—A New Bulking Agent for the Treatment of Women with Stress Urinary Incontinence: Outcome of 12 Months Follow Up

Table 1

Efficacy outcomes versus baseline (visit I) characteristics after 6 weeks (visit II), 3 months (visit III), and 12 months (visit IV).

	Stamey grade	1 hr pad test-weight (g)	Incontinence episodes (24 h)	I-QoL	Number of pads (72 hr)
Baseline (𝑁=20)	1.9 (0.79)	20.2 (24.28)	6.1 (6.70)	50.7 (20.09)	17.3 (14.91)
Visit II (𝑁=20)	0.75 (0.73)^‡	5.5 (13.98)^‡	2.5 (2.7)^‡	64.0 (24.12)^$	8.7 (8.70)^‡
Visit III (𝑁=20)	0.2 (0.41)^‡	1.6 (2.80)^‡	1.7 (1.9)^‡	81.9 (21.30)^‡	5.4 (7.06)^‡
Visit IV (𝑁=19)	0.4 (0.69)^‡	7.8 (19.92)^‡	1.6 (1.77)^‡	75.5 (20.98)^‡	5.6 (7.22)^‡

^‡𝑃<0.001 for all visits versus baseline.
^$𝑃<0.01 for visit II versus baseline.
Values presented in mean (SD).